Patel Snehal purchased $20K of GLSI

Patel Snehal (CEO and CFO) purchased 1,500 shares of Greenwich LifeSciences, Inc. (GLSI) at $13.62 on 2026-07-27.

Original reporting
SEC EDGAR · Patel Snehal
Published Jul 29, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GLSI
Bullish
low confidence
Mentioned
$GLSI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLSIBullishLow
01

Why it matters

The only new information is the CEO/CFO’s open-market purchase details (shares, price, total value, and post-transaction holdings). No guidance, trial results, contracts, or regulatory actions are mentioned.

02

Market read

Traders may treat the filing as a mild sentiment input, but it is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on prior trading patterns, options exercises, or compensation-related flows.

Relevance 4/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-29)

Background

This is an SEC Form 4 insider transaction disclosure for Greenwich LifeSciences, Inc. (GLSI).

Company-level read

Ticker impact

$GLSIBullishLow confidence
Context

Greenwich LifeSciences CEO/CFO Patel Snehal bought 1,500 shares at $13.62 on 2026-07-27, totaling $20,430, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small given the transaction size.

Evidence & confidence

The filing is primary-source and directly tied to GLSI, but the dollar value ($20.4k) is relatively small versus typical market-moving thresholds, and no new operating/financial information is disclosed.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and do not necessarily signal improved fundamentals, especially at small dollar sizes.

Key entities

  • Greenwich LifeSciences, Inc.

    Subject of the Form 4 insider purchase by CEO/CFO Patel Snehal.

  • Patel Snehal

    CEO and CFO, reported open-market purchase of 1,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.